Diffuse Large B-Cell Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

DLBCL MCID: DFF005 MIFTS: 55	Diffuse Large B-Cell Lymphoma (DLBCL) Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Diffuse Large B-Cell Lymphoma:

Name: Diffuse Large B-Cell Lymphoma ¹¹ ¹⁹ ⁵⁸ ¹⁴ ³⁶ ¹⁶ ⁷¹ ⁷⁵ ³¹

Dlbcl ¹¹ ¹⁹ ⁵⁸

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified ⁷¹ ³³

Dlbcl - [diffuse Large B-Cell Lymphoma] ³³

Diffuse Large Beta Cell Lymphoma ³³

Lymphoma, Large B-Cell, Diffuse ⁴³

Large B-Cell Diffuse Lymphoma ⁷⁵

Characteristics:

Inheritance:

Multigenic/multifactorial ⁵⁸

Prevelance:

1-5/10000 (Europe) 1-9/100000 (France, Europe, Austria, Belgium, Bulgaria, Czech Republic, Estonia, Finland, Germany, Iceland, Ireland, Italy, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-9/1000000 (Croatia, Latvia) ⁵⁸

Age Of Onset:

Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Non-follicular lymphoma

Diffuse large B-cell lymphoma

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Mature B-cell neoplasms

Diffuse large B-cell lymphomas

Diffuse large B-cell lymphoma, not otherwise specified

Other specified diffuse large B-cell lymphomas

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:0050745

MeSH ⁴³ D016403

NCIt ⁴⁹ C80280

ICD10 ³¹ C83.3

MESH via Orphanet ⁴⁴ D016403

ICD10 via Orphanet ³² C83.3

UMLS via Orphanet ⁷² C0079744

Orphanet ⁵⁸ ORPHA544

EFO ¹⁶ EFO_0000403

ICD11 ³³ 1946973604 1946973604/other 1946973604/unspecified

UMLS ⁷¹ C0079744 C2699777

Sources

Summaries for Diffuse Large B-Cell Lymphoma

GARD: ¹⁹ Diffuse Large B-Cell Lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common blood cancer. Lymphomas occur when cells of the immune system, known as B lymphocytes, grow and multiply uncontrollably. DLBCL occurs mostly in adults and is a fast-growing (aggressive) lymphoma. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss.

MalaCards based summary: Diffuse Large B-Cell Lymphoma, also known as dlbcl, is related to burkitt lymphoma and lymphoma, non-hodgkin, familial. An important gene associated with Diffuse Large B-Cell Lymphoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways are Cell differentiation - expanded index and miRNAs involvement in the immune response in sepsis. The drugs Lomustine and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and breast.

Orphanet: ⁵⁸ Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma (NHL; see this term) in adults characterized by a median age of presentation in the sixth decade of life (but also rarely occurring in adolescents and children) with the initial presentation being single or multiple rapidly growing masses (that may or may not be painful) in nodal or extranodal sites (such as thyroid, skin, breast, gastrointestinal tract, testes, bone, or brain) and that can be accompanied by symptoms of fever, night sweats and weight loss. DLBCL has an aggressive disease course, with the elderly having a poorer prognosis than younger patients, and with relapses being common.

Disease Ontology: ¹¹ A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.

Wikipedia: ⁷⁵ Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible... more...

Sources

Related Diseases for Diffuse Large B-Cell Lymphoma

Diseases in the Diffuse Large B-Cell Lymphoma family:

Bn2 Diffuse Large B-Cell Lymphoma	N1 Diffuse Large B-Cell Lymphoma
St2 Diffuse Large B-Cell Lymphoma	A53 Diffuse Large B-Cell Lymphoma

Diseases related to Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1129)

#	Related Disease	Score	Top Affiliating Genes
1	burkitt lymphoma	33.4	MIR21 MIR17HG MIR155 MIR150 MIR145 MIR143
2	lymphoma, non-hodgkin, familial	32.7	MIR21 MIR17 MIR155 MIR151A MIR145 MIR143
3	leukemia, chronic lymphocytic	31.9	PEG10 MIR21 MIR17HG MIR17 MIR155 MIR151A
4	hematologic cancer	31.9	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
5	peripheral t-cell lymphoma	31.7	MIR21 MIR17 MIR155
6	immune deficiency disease	31.7	MIR210 MIR21 MIR17 MIR155 MIR150
7	peripheral nervous system disease	31.7	MIR21 MIR17 MIR151A MIR145 MIR143 MIR127
8	myeloma, multiple	31.6	MIR21 MIR17 MIR155 MIR145 HOTAIR
9	leukemia, acute lymphoblastic	31.6	MIR210 MIR21 MIR17 MIR155 MIR151A
10	leukemia, acute myeloid	31.6	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
11	mature t-cell and nk-cell lymphoma	31.5	MIR21 MIR17 MIR155
12	leukemia, chronic myeloid	31.4	MIR17 MIR155 MIR151A MIR127 HULC HOTAIR
13	primary cutaneous t-cell non-hodgkin lymphoma	31.3	MIR21 MIR17 MIR155
14	dermatomyositis	31.2	MIR210 MIR21 MIR155
15	brain cancer	31.2	MIR21 MIR17 MIR155 MIR145 MIR143
16	lymphatic system disease	31.1	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
17	rectal benign neoplasm	31.1	MIR17 MIR145 MIR143
18	t-cell acute lymphoblastic leukemia	31.1	MIR17 MIR155 MIR143 LUNAR1
19	nasopharyngeal carcinoma	31.1	MIR21 MIR17 MIR155 MIR151A MIR150 MIR145
20	central nervous system disease	31.1	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
21	rectum cancer	31.0	MIR21 MIR17 MIR150 MIR145 MIR143
22	colonic benign neoplasm	31.0	MIR21 MIR145 MIR143
23	nervous system disease	31.0	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
24	gastrointestinal system disease	31.0	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
25	polymyositis	31.0	MIR210 MIR21 MIR155 MIR127
26	connective tissue disease	31.0	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
27	lung cancer susceptibility 3	31.0	MIR21 MIR17 MIR150 MIR145 MIR143 HOTAIR
28	pancreatic cancer	31.0	MIR210 MIR21 MIR17 MIR155 MIR145 MIR143
29	bladder cancer	31.0	PANDAR MIR21 MIR17 MIR145 MIR143 MIR127
30	lung cancer	30.9	PANDAR MIR210 MIR21 MIR17HG MIR17 MIR155
31	high grade glioma	30.9	MIR21 MIR17 MIR155 MIR145 HULC HOTAIR
32	bone disease	30.9	MIR210 MIR21 MIR17 MIR155 MIR143 MIR127
33	pleural disease	30.9	MIR21 MIR17 MIR150
34	gallbladder cancer	30.8	MIR17 MIR145 MIR143 HOTAIR
35	myocardial infarction	30.8	MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
36	ocular cancer	30.8	MIR21 MIR17 MIR155 MIR143
37	colorectal adenocarcinoma	30.7	MIR17 MIR145 MIR143
38	type 2 diabetes mellitus	30.7	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
39	renal cell carcinoma, nonpapillary	30.7	PANDAR MIR210 MIR21 MIR17 MIR155 MIR150
40	retinal disease	30.7	MIR210 MIR21 MIR17 MIR155
41	glioma	30.7	MIR210 MIR21 MIR17 HULC HOTAIR
42	arteries, anomalies of	30.6	MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
43	cardiovascular system disease	30.6	MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
44	gastric cancer	30.6	PANDAR MIR21 MIR17 MIR150 MIR145 MIR143
45	kidney cancer	30.6	MIR210 MIR21 MIR17 MIR150 MIR145 HOTAIR
46	lipoprotein quantitative trait locus	30.6	MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
47	pancreatic ductal adenocarcinoma	30.6	MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
48	lymphatic system cancer	30.6	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150
49	gallbladder disease	30.5	MIR17 MIR145 MIR143
50	intestinal disease	30.5	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma:

Sources

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma

Sources

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma

Drugs for Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 358)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lomustine

Approved, Investigational

Phase 4

13010-47-4

3950

Idarubicin

Approved

Phase 4

58957-92-9

42890

Rivoceranib

Investigational

Phase 4

811803-05-1

11315474

Mitogens

Phase 4

Endothelial Growth Factors

Phase 4

HIV Protease Inhibitors

Phase 4

BB 1101

Phase 4

protease inhibitors

Phase 4

Lamivudine

Approved, Investigational

Phase 2, Phase 3

134678-17-4

60825

Aldesleukin

Approved

Phase 3

110942-02-4

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Coenzyme M

Approved, Investigational

Phase 3

3375-50-6

598 23662354

Darbepoetin alfa

Approved, Investigational

Phase 3

209810-58-2

Pixantrone

Approved, Investigational

Phase 3

144510-96-3

134019

Vinblastine

Approved

Phase 3

865-21-4

241903 13342

Vidarabine

Approved, Investigational

Phase 3

24356-66-9

21704

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Decitabine

Approved, Investigational

Phase 3

2353-33-5

451668

Epirubicin

Approved

Phase 3

56420-45-2

41867

Cladribine

Approved, Investigational

Phase 3

4291-63-8

20279

Sargramostim

Approved, Investigational

Phase 3

123774-72-1

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

43805 11947679 6857599

Obinutuzumab

Approved, Investigational

Phase 3

949142-50-1

Avelumab

Approved, Investigational

Phase 3

1537032-82-8

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Bleomycin

Approved, Investigational

Phase 3

9041-93-4, 11056-06-7

5360373

Vindesine

Approved, Investigational

Phase 3

59917-39-4, 53643-48-4

40839

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Buformin

Investigational, Withdrawn

Phase 2, Phase 3

692-13-7

2468

Cortisone

Experimental

Phase 2, Phase 3

53-06-5

222786

Molgramostim

Investigational

Phase 3

99283-10-0

Prednisolone hemisuccinate

Experimental

Phase 3

2920-86-7

4897

Interleukin-2

Phase 3

Analgesics, Non-Narcotic

Phase 3

Analgesics

Phase 3

Fluorodeoxyglucose F18

Phase 3

Epoetin Alfa

Phase 3

Hematinics

Phase 3

Cc-486

Phase 2, Phase 3

Vaccines

Phase 3

Immunoglobulin Idiotypes

Phase 3

Interventional clinical trials:

(show top 50) (show all 1161)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma	Unknown status	NCT01949818	Phase 4	Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2	Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma	Unknown status	NCT03513601	Phase 4	(R)-CHOP regimen;(R)-CVP regimen
3	A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma	Unknown status	NCT03579082	Phase 4	Decitabine
4	LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)	Completed	NCT00466258	Phase 4	R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
5	Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study	Completed	NCT03376958	Phase 4	Apatinib
6	B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021)	Recruiting	NCT05518383	Phase 4	Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
7	Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma.	Active, not recruiting	NCT02752815	Phase 4	Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
8	Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma	Unknown status	NCT03018626	Phase 3	Rituximab;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide;Prednisone;Vindesine;Bleomycin
9	Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma	Unknown status	NCT02767674	Phase 3	Rituximab;Gemcitabine;Oxaliplatin;Cyclophosphamide;Epirubicin Injectable Product;Vindesine;Prednisone
10	R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail	Unknown status	NCT00846157	Phase 3
11	An Randomized, Open-label, Phase III Study Comparing Thalidomide Combined With R-CHOP and R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients	Unknown status	NCT03318835	Phase 3	Thalidomide combined with R-CHOP;R-CHOP
12	Multicenter, Randomized, Double-blind, Parallel Controlled, Phase III Clinical Study to Compare the Efficacy and Safety of TQB2303 in Conbination With CHOP Regimen (T-CHOP) Versus Rituximab in Combination With CHOP Regimen (R-CHOP) in Previously Untreated Subjects With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)	Unknown status	NCT03777085	Phase 3	TQB2303;Rituximab
13	A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells.	Unknown status	NCT00499018	Phase 3	Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;VP-16
14	A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B	Unknown status	NCT01852435	Phase 3	R-CEOP-70;R-CEOP-90;R-CHOP-50
15	Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study	Unknown status	NCT02777736	Phase 3	Methotrexate
16	Prospective, Multicenter, Randomized ,Open-labeled, Phase III Study Comparing High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for the Prophylaxis of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma	Unknown status	NCT03123718	Phase 3	Intrathecal methotrexate;High-dose intravenous methotrexate
17	A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma	Unknown status	NCT03151044	Phase 3	High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
18	Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study	Unknown status	NCT02428751	Phase 3	Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
19	Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation	Unknown status	NCT03229616	Phase 2, Phase 3	Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
20	A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients	Unknown status	NCT03650933	Phase 3
21	Cinobufacini Tablets Combined With R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone)/CHOP in Treatment of Diffuse Large B Cell Lymphoma: A Phase II Randomized, Controlled and Multi-center Study	Unknown status	NCT02871869	Phase 2, Phase 3	vindesine;cyclophosphamide;Epirubicin;prednisone tablets;Cinobufacini Tablets;Rituximab
22	Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy	Unknown status	NCT01156259	Phase 3
23	Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study	Unknown status	NCT01210287	Phase 2, Phase 3	nucleoside analog reverse transcriptase inhibitor
24	A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients	Unknown status	NCT02772822	Phase 3	SCT400 plus CHOP;Rituximab plus CHOP
25	A Phase III, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of SIBP-02 (Rituximab Biosimilar) and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL	Unknown status	NCT04361279	Phase 3	SIBP-02;Rituximab
26	A Multicenter,Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH and R-CEOP90, With or Without Upfront Auto-HSCT，in Newly Diagnosed Young Patients With Intermediate/High-risk DLBCL	Unknown status	NCT03213977	Phase 3	R-DA-EPOCH;R-DA-EPOCH + auto-HSCT;R-CEOP90;R-CEOP90 + auto-HSCT
27	High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial	Unknown status	NCT02531841	Phase 3	Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
28	Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients	Unknown status	NCT01277172	Phase 2, Phase 3
29	Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.	Completed	NCT01805557	Phase 2, Phase 3	R-DHAP;BR-DHAP
30	Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association	Completed	NCT02128061	Phase 3	Lenalidomide;Rituximab
31	SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma	Completed	NCT00491491	Phase 3	ibritumomab tiuxetan
32	Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma	Completed	NCT02617485	Phase 3	Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
33	Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma	Completed	NCT02285062	Phase 3	lenalidomide;Placebo;Rituximab;Cyclophosphamide;Doxorubicin;prednisone;vincristine
34	A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)	Completed	NCT01889069	Phase 3	Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
35	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.	Completed	NCT04236141	Phase 3	Polatuzumab Vedotin;Bendamustine;Rituximab;Placebo
36	A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line	Completed	NCT02268045	Phase 3
37	Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma.	Completed	NCT01987505	Phase 3	Rituximab
38	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma	Completed	NCT01855750	Phase 3	Ibrutinib;Placebo;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone (or equivalent)
39	A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy	Completed	NCT00790036	Phase 3	Everolimus;Everolimus Placebo
40	Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.	Completed	NCT00140595	Phase 3	rituximab;doxorubicin;cyclophosphamide
41	Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.	Completed	NCT00144755	Phase 3	Darbepoetin alfa
42	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)	Completed	NCT01014208	Phase 3	OFATUMUMAB + DHAP;RITUXIMAB + DHAP
43	A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™	Completed	NCT03263026	Phase 3	Enzastaurin Hydrochloride
44	Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma	Completed	NCT00169130	Phase 2, Phase 3	doxorubicin;cyclophosphamide
45	Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab	Completed	NCT00137995	Phase 3	Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Cytarabine;Melphalan
46	A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)	Completed	NCT01649856	Phase 3	CHOP;rituximab [MabThera/Rituxan]
47	A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma	Completed	NCT03372837	Phase 3	Rituximab
48	A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)	Completed	NCT01148446	Phase 3	Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
49	A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL)	Completed	NCT02867566	Phase 3	IBI301 plus CHOP;Rituximab plus CHOP
50	A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Completed	NCT01197560	Phase 2, Phase 3	Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Diffuse Large B-Cell Lymphoma cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Diffuse Large B-Cell Lymphoma:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	Peripheral blood stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Diffuse Large B-Cell Lymphoma:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, large b-cell, diffuse

Sources

Genetic Tests for Diffuse Large B-Cell Lymphoma

Sources

Anatomical Context for Diffuse Large B-Cell Lymphoma

Organs/tissues related to Diffuse Large B-Cell Lymphoma:

MalaCards : B Cells, T Cells, Breast, Thyroid, Bone, Testes, Bone Marrow

Sources

Publications for Diffuse Large B-Cell Lymphoma

Articles related to Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 16526)

#	Title	Authors	PMID	Year
1	Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. ⁶² ⁴⁶	Robertus JL...van den Berg A	19287466	2009
2	MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. ⁶² ⁴⁶	Roehle A...Feller AC	18537969	2008
3	Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. ⁶² ⁴⁶	Lawrie CH...Harris AL	18318758	2008
4	MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. ⁶² ⁴⁶	Lawrie CH...Hatton CS	17487835	2007
5	BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. ⁶² ⁴⁶	Kluiver J...van den Berg A	16041695	2005
6	Accumulation of miR-155 and BIC RNA in human B cell lymphomas. ⁶² ⁴⁶	Eis PS...Dahlberg JE	15738415	2005
7	Downregulation of microRNAs-143 and -145 in B-cell malignancies. ⁴⁶	Akao Y...Naoe T	17892514	2007
8	MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. ⁴⁶	Martin MM...Elton TS	16675453	2006
9	Total Knee Arthroplasty Complicated by Diffuse Large B-Cell Lymphoma. ⁶²	Wetzel R...Lyons S	36465694	2023
10	Hemophagocytic lymphohistiocytosis secondary to diffuse large B-cell lymphoma presenting with recurrent multi-territory infarcts: A case report. ⁶²	Quyen PTN...Thang NB	36411855	2023
11	Potential Role of 68Ga-NOTA-Duramycin PET/CT Imaging for Early Response Evaluation in a Lymphoma Patient: A Case Report. ⁶²	Kaur G...Mittal BR	36469075	2023
12	Poly zinc finger protein ZFP14 suppresses lymphomagenesis and abnormal inflammatory response via the HOXA gene cluster. ⁶²	Mohibi S...Zhang J	36349645	2023
13	Multi-scale feature similarity-based weakly supervised lymphoma segmentation in PET/CT images. ⁶²	Huang Z...Ruan S	36306574	2022
14	TBL1X: At the crossroads of transcriptional and posttranscriptional regulation. ⁶²	Pray BA...Alinari L	36206873	2022
15	The dual role of CD70 in B-cell lymphomagenesis. ⁶²	Nie M...Pan-Hammarstrom Q	36471481	2022
16	Biological and clinical significance of epigenetic alterations in B-cell lymphomas. ⁶²	Ennishi D	36208393	2022
17	18 F-FDG Whole-Body PET-MR in Primary Hepatic Lymphoma Mimicking Focal Nodular Hyperplasia. ⁶²	Basheer S...Palaniswamy SS	36398300	2022
18	Characteristics and Outcomes of Alberta Lymphoma Patients with a History of Immunosuppressive therapy for Autoimmune Conditions. ⁶²	Kantharia K...Dersch-Mills D	36031543	2022
19	Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. ⁶²	Wood AC...Jain MD	36174934	2022
20	18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients. ⁶²	Girum KB...Buvat I	35710733	2022
21	Top advances in lymphoma for 2021. ⁶²	Patel DA...Kahl BS	36201139	2022
22	Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study. ⁶²	Iovino L...Shadman M	36453136	2022
23	Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan. ⁶²	Takimoto-Ito R...Kabashima K	36470790	2022
24	Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. ⁶²	Figura NB...Robinson TJ	36369950	2022
25	Comparison of pyrrolobenzodiazepine dimer bis-imine versus mono-imine: DNA interstrand cross-linking, cytotoxicity, and antibody-drug conjugate efficacy and toxicity. ⁶²	Tiberghien AC...Howard PW	36474428	2022
26	Follicular lymphoma: 2023 update on diagnosis and management. ⁶²	Jacobsen E	36255040	2022
27	Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies. ⁶²	Hernandez-Verdin I...Alentorn A	36367044	2022
28	Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12. ⁶²	Nagao T...Nogami A	36191884	2022
29	Genome wide exploration of the methylome in aggressive B-cell lymphoma in Golden Retrievers reveals a conserved hypermethylome. ⁶²	Chu S...Bryan JN	35912844	2022
30	Epidemiological features for primary lymphoma of the female genital tract patients and development of a nomogram to predict survival. ⁶²	Peng F...Hu Y	35416104	2022
31	Prognostic role of controlling nutritional status score in hematological malignancies. ⁶²	Zhang Y...Yu L	35622088	2022
32	SLP76 Mutation Associated with Combined Immunodeficiency and EBV-Related Lymphoma. ⁶²	Lev A...Somech R	36474126	2022
33	Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. ⁶²	Wang L...Ortonne N	35895386	2022
34	Circulating Tumor DNA in Lymphoma. ⁶²	Kambhampati S...Zain J	36214943	2022
35	Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. ⁶²	Baptista MJ...Navarro JT	36109172	2022
36	Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel. ⁶²	Cutini I...Saccardi R	36116729	2022
37	Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study. ⁶²	Shi Y...Ling Y	36040107	2022
38	Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities. ⁶²	Song JY...Campo E	36459219	2022
39	Diffuse Large B-Cell Lymphoma in the Public-Sector of Johannesburg, South Africa, in the Era of Widescale Antiretroviral Therapy Use. ⁶²	Vaughan J...Wiggill T	35916644	2022
40	Herbicide use in farming and other jobs in relation to non-Hodgkin's lymphoma (NHL) risk. ⁶²	De Roos AJ...Cerhan JR	36207110	2022
41	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. ⁶²	Broglio K...Berry DA	35815677	2022
42	B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers. ⁶²	McLachlan T...Dun MD	36166198	2022
43	Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition. ⁶²	Yuti P...Sujjitjoon J	36435066	2022
44	Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. ⁶²	Zhang N...Wang Z	36252471	2022
45	Ocular recurrence of diffuse large B-cell lymphoma originating from central nervous system: A case report. ⁶²	Lu YD...Zhao HY	35750610	2022
46	Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis. ⁶²	Zhao J...Zhou D	35754389	2022
47	Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience ⁶²	Ozbalak M...Kalayoglu Besisik S	35657203	2022
48	Outcomes of high‑dose methotrexate for CNS prophylaxis in diffuse large B‑cell lymphoma with an intermediate or high CNS‑International Prognostic Index: A single‑center retrospective cohort study. ⁶²	Al-Mansour M...Alsaeed A	36338604	2022
49	CAPG facilitates diffuse large B-cell lymphoma cell progression through PI3K/AKT signaling pathway. ⁶²	Wang G...Zhang Q	36244872	2022
50	[New European approval: Polatuzumab vedotin associated to rituximab, cyclophosphamide, doxorubicin and prednisone in previously untreated Diffuse Large B-Cell Lymphoma]. ⁶²	Turot M...Aspas Requena G	36441028	2022

Sources

Genes for Diffuse Large B-Cell Lymphoma

Genes related to Diffuse Large B-Cell Lymphoma (3 elite genes):

(show top 50) (show all 114)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR155	MicroRNA 155	RNA Gene	419.87	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	16675453 15738415
2	MIR145	MicroRNA 145	RNA Gene	408.12	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	17892514 18537969
3	MIR143	MicroRNA 143	RNA Gene	354.94	Causal ⁴⁶ DISEASES inferred ¹⁴	17892514
4	MIR17HG	MiR-17-92a-1 Cluster Host Gene	RNA Gene	156.61	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	15126345
5	MEF2C-AS2	MEF2C Antisense RNA 2	RNA Gene	155.59	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27292966
6	CSMD2-AS1	CSMD2 Antisense RNA 1	RNA Gene	155.56	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27292966
7	MME-AS1	MME Antisense RNA 1	RNA Gene	155.48	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27292966
8	SACS-AS1	SACS Antisense RNA 1	RNA Gene	155.37	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27292966
9	LUNAR1	Leukemia-Associated Non-Coding IGF1R Activator RNA 1	RNA Gene	155.36	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26796267
10	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	155.3	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27550047
11	PEG10	Paternally Expressed 10	Protein Coding	155.28	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25864113
12	B3GAT1-DT	B3GAT1 Divergent Transcript	RNA Gene	150	Experimental evidence ³⁷	25133503
13	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	27044827
14	PANDAR	Promoter Of CDKN1A Antisense DNA Damage Activated RNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	29069778
15	MIR17	MicroRNA 17	RNA Gene	67.92	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18537969
16	MIR127	MicroRNA 127	RNA Gene	62.52	Unspecified ⁴⁶ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	19287466
17	MIR21	MicroRNA 21	RNA Gene	59.82	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	17487835
18	MIR151A	MicroRNA 151a	RNA Gene	57.88	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18537969
19	MIR150	MicroRNA 150	RNA Gene	55.92	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
20	MIR210	MicroRNA 210	RNA Gene	55.75	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18318758
21	MIR221	MicroRNA 221	RNA Gene	55.6	Unspecified ⁴⁶ DISEASES inferred ¹⁴	17487835
22	MIR106A	MicroRNA 106a	RNA Gene	55.25	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
23	MIR99A	MicroRNA 99a	RNA Gene	54.91	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
24	MIR10A	MicroRNA 10a	RNA Gene	54.78	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
25	MIRLET7E	MicroRNA Let-7e	RNA Gene	54.37	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
26	MIR328	MicroRNA 328	RNA Gene	54.05	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
27	MIR149	MicroRNA 149	RNA Gene	54.04	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
28	MIR95	MicroRNA 95	RNA Gene	53.87	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
29	MIR139	MicroRNA 139	RNA Gene	53.85	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
30	MIR320A	MicroRNA 320a	RNA Gene	53.53	Unspecified ⁴⁶ DISEASES inferred ¹⁴	18537969
31	BCL6	BCL6 Transcription Repressor	Protein Coding	39.85	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Pathways & Interactions (show sections)
31	BCL6::MIR127 ⁴⁶	MIR127 Macro RNA (hsa-miR-127) targets BCL6
32	PASD1	PAS Domain Containing Repressor 1	Protein Coding	33.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries Expressions (show sections)
33	BCL2	BCL2 Apoptosis Regulator	Protein Coding	28.56	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
34	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	28.25	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
35	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	26.5	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
36	CD274	CD274 Molecule	Protein Coding	26.26	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
37	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	25.93	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
38	PRDM1	PR/SET Domain 1	Protein Coding	25.86	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
39	KMT2D	Lysine Methyltransferase 2D	Protein Coding	24.48	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
40	REL	REL Proto-Oncogene, NF-KB Subunit	Protein Coding	24.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
41	GCSAM	Germinal Center Associated Signaling And Motility	Protein Coding	24.34	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
42	MDM2	MDM2 Proto-Oncogene	Protein Coding	23.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
43	MAPK3	Mitogen-Activated Protein Kinase 3	Protein Coding	23.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
44	CDK4	Cyclin Dependent Kinase 4	Protein Coding	22.93	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
45	KDM2B	Lysine Demethylase 2B	Protein Coding	22.46	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
46	H2AX	H2A.X Variant Histone	Protein Coding	22.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
47	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	22.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Pathways & Interactions (show sections)
48	GLI1	GLI Family Zinc Finger 1	Protein Coding	21.86	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
49	FBXO11	F-Box Protein 11	Protein Coding	14.44	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
50	SUZ12	SUZ12 Polycomb Repressive Complex 2 Subunit	Protein Coding	14.41	DISEASES inferred ¹⁴ GeneCards inferred via : Pathways & Interactions (show sections)

Sources

Variations for Diffuse Large B-Cell Lymphoma

Copy number variations for Diffuse Large B-Cell Lymphoma from CNVD:

⁶ (show top 50) (show all 118)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13828	1	1	84900000	Loss		Diffuse large b-cell lymphoma
2	17406	1	142600000	249250621	Gain		Diffuse large b-cell lymphoma
3	20082	1	15300000	163800000	Gain		Diffuse large b-cell lymphoma
4	38345	10	101900000	103000000	Gain		Diffuse large b-cell lymphoma
5	38773	10	104900000	105800000	Gain		Diffuse large b-cell lymphoma
6	38901	10	105800000	121700000	Loss		Diffuse large b-cell lymphoma
7	40597	10	130600000	135534747	Loss		Diffuse large b-cell lymphoma
8	43294	10	46100000	64500000	Loss		Diffuse large b-cell lymphoma
9	48479	11	1	43500000	Gain		Diffuse large b-cell lymphoma
10	51204	11	123900000	135006516	Loss		Diffuse large b-cell lymphoma
11	53206	11	26100000	36400000	Loss		Diffuse large b-cell lymphoma
12	55792	11	55700000	135006516	Gain		Diffuse large b-cell lymphoma
13	64291	12	12600000	14800000	Gain	CDKN1B	Diffuse large b-cell lymphoma
14	70914	12	66000000	69800000	Gain	MDM2	Diffuse large b-cell lymphoma
15	74343	13	104800000	110300000	Loss		Diffuse large b-cell lymphoma
16	74383	13	105800000	109100000	Loss		Diffuse large b-cell lymphoma
17	75387	13	19500000	55300000	Gain		Diffuse large b-cell lymphoma
18	76712	13	35500000	75400000	Loss		Diffuse large b-cell lymphoma
19	79280	13	68600000	115169878	Gain		Diffuse large b-cell lymphoma
20	86223	14	55800000	61200000	Loss		Diffuse large b-cell lymphoma
21	88116	14	84900000	107349540	Loss		Diffuse large b-cell lymphoma
22	90236	15	20700000	102531392	Loss		Diffuse large b-cell lymphoma
23	97251	16	1	34600000	Gain		Diffuse large b-cell lymphoma
24	97373	16	1	7900000	Gain	ABCA3	Diffuse large b-cell lymphoma
25	97375	16	1	7900000	Gain	ECI1	Diffuse large b-cell lymphoma
26	97377	16	1	7900000	Gain	E4F1	Diffuse large b-cell lymphoma
27	97379	16	1	7900000	Gain	HAGH	Diffuse large b-cell lymphoma
28	97381	16	1	7900000	Gain	IGFALS	Diffuse large b-cell lymphoma
29	97383	16	1	7900000	Gain	MRPS34	Diffuse large b-cell lymphoma
30	97385	16	1	7900000	Gain	NME3	Diffuse large b-cell lymphoma
31	97387	16	1	7900000	Gain	NUBP2	Diffuse large b-cell lymphoma
32	97391	16	1	7900000	Gain	RNPS1	Diffuse large b-cell lymphoma
33	99692	16	28100000	36600000	Loss		Diffuse large b-cell lymphoma
34	102840	16	57400000	90354753	Gain		Diffuse large b-cell lymphoma
35	102843	16	57400000	90354753	Loss		Diffuse large b-cell lymphoma
36	104071	16	66700000	70800000	Gain	DDX19B	Diffuse large b-cell lymphoma
37	104073	16	66700000	70800000	Gain	FCSK	Diffuse large b-cell lymphoma
38	104075	16	66700000	70800000	Gain	ST3GAL2	Diffuse large b-cell lymphoma
39	106530	16	88700000	90354753	Gain		Diffuse large b-cell lymphoma
40	106806	17	1	22200000	Loss		Diffuse large b-cell lymphoma
41	111431	17	3600000	6800000	Loss	TP53	Diffuse large b-cell lymphoma
42	120634	18	2900000	78077248	Gain		Diffuse large b-cell lymphoma
43	121454	18	43500000	48200000	Gain		Diffuse large b-cell lymphoma
44	121719	18	46400000	52000000	Gain	BCL2	Diffuse large b-cell lymphoma
45	122173	18	53800000	56200000	Gain	MALT1	Diffuse large b-cell lymphoma
46	123098	18	66800000	68700000	Loss		Diffuse large b-cell lymphoma
47	123108	18	66900000	71300000	Gain		Diffuse large b-cell lymphoma
48	127687	19	35500000	38300000	Gain	KIRREL2	Diffuse large b-cell lymphoma
49	127689	19	35500000	38300000	Gain	KMT2B	Diffuse large b-cell lymphoma
50	127691	19	35500000	38300000	Gain	NPHS1	Diffuse large b-cell lymphoma

Sources

Expression for Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma.

Sources

Pathways for Diffuse Large B-Cell Lymphoma

Pathways related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.25	MIR17 MIR155 MIR150 MIR145 MIR143
2	miRNAs involvement in the immune response in sepsis ⁷⁴	11.12	MIR21 MIR155 MIR145
3	miRNAs involved in DNA damage response ⁷⁴	10.85	MIR210 MIR21 MIR17 MIR145 MIR143

Sources

GO Terms for Diffuse Large B-Cell Lymphoma

Cellular components related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.58	MIR210 MIR21 MIR17HG MIR17 MIR155 MIR150

Biological processes related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	miRNA-mediated gene silencing	GO:0035195	9.6	MIR210 MIR21 MIR17HG MIR17 MIR155 MIR151A
2	angiotensin-activated signaling pathway	GO:0038166	9.49	MIR145 MIR143
3	aorta smooth muscle tissue morphogenesis	GO:0060414	9.48	MIR145 MIR143
4	positive regulation of metalloendopeptidase activity	GO:1904685	9.46	MIR21 MIR17
5	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.46	MIR210 MIR21 MIR17 MIR145
6	negative regulation of BMP secretion	GO:2001285	9.43	MIR210 MIR17
7	regulation of phenotypic switching	GO:1900239	9.4	MIR145 MIR143
8	positive regulation of pulmonary blood vessel remodeling	GO:1905111	9.37	MIR17 MIR143
9	positive regulation of cellular response to hypoxia	GO:1900039	9.32	MIR21 MIR145
10	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	9.26	MIR145 MIR143
11	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.13	MIR17 MIR21 MIR210

Molecular functions related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.56	MIR210 MIR21 MIR17 MIR155 MIR151A MIR145
2	mRNA base-pairing translational repressor activity	GO:1903231	9.28	MIR210 MIR21 MIR17 MIR155 MIR151A MIR150